What Aspects Will Give Humira Biosimilars The Edge In 2023?
Vizient Report Examines Views Of Pharmacy Executives And Professionals
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.
